LPCN
Lipocine·NASDAQ
--
--(--)
--
--(--)
LPCN fundamentals
Lipocine (LPCN) released its earnings on Aug 5, 2025: revenue was 622.85K (YoY +595.42%), beat estimates; EPS was -0.41 (YoY +26.79%), missed estimates.
Revenue / YoY
622.85K
+595.42%
EPS / YoY
-0.41
+26.79%
Report date
Aug 5, 2025
Earnings Call
6:00 AM on Aug 5, 2025
Meeting link.EPS
Actual | -2.38 | -2.21 | -1.19 | -3.06 | -0.68 | -1.36 | -0.51 | 2.38 | -0.68 | -0.68 | -0.51 | -0.34 | -0.68 | -0.68 | -1.27 | -0.51 | 0.66 | -0.56 | -0.44 | 0.33 | -0.35 | -0.41 | |||||||||
Forecast | -1.36 | -1.19 | -1.02 | -1.0767 | -0.85 | -0.85 | -0.7225 | -0.17 | -0.34 | -0.68 | -0.5667 | -0.51 | -0.425 | -0.64 | -0.6 | -0.47 | -0.6822 | -0.78 | -0.485 | -0.4 | -0.35 | -0.4 | |||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -75.00% | -85.71% | -16.67% | -184.20% | +20.00% | -60.00% | +29.41% | +1500.00% | -100.00% | 0.00% | +10.01% | +33.33% | -60.00% | -6.25% | -111.67% | -8.51% | +196.75% | +28.21% | +9.28% | +182.50% | 0.00% | -2.50% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0 | 0 | 0 | 0 | 0 | 54.99K | 16.10M | 0 | 500.00K | 0 | 0 | 54.99K | 0 | -3.12M | 200.00K | 7.62M | 89.56K | 0 | 3.50M | 93.86K | 622.85K |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0 | 0 | -- | 0 | 0 | 5.50M | 4.00M | 257.00K | 698.67K | 1.31M | 777.00K | 256.00K | 307.00K | 0 | 0 | 290.00K | 129.50K | 2.61M | 352.00K | 229.00K |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +192.73% | -100.00% | +94.55% | -100.00% | -100.00% | -92.92% | -100.00% | -1116.94% | 0.00% | 0.00% | -69.12% | -100.00% | +33.72% | -73.33% | +171.99% |
Earnings Call
You can ask Aime
What is the market's earnings forecast for Lipocine next quarter?What were the key takeaways from Lipocine's earnings call?What guidance did Lipocine's management provide for the next earnings period?What does Lipocine do and what are its main business segments?What is the revenue and EPS growth rate for Lipocine year over year?What were the key takeaways from Lipocine’s earnings call?Did Lipocine beat or miss consensus estimates last quarter?What factors drove the changes in Lipocine's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
